<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308021</url>
  </required_header>
  <id_info>
    <org_study_id>BTT-gpASIT005</org_study_id>
    <nct_id>NCT01308021</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis</brief_title>
  <official_title>Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioTech Tools S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioTech Tools S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived
      peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of gpASIT+TM on the clinical efficacy of the subjects</measure>
    <time_frame>grass pollen season 2011 (April to July)</time_frame>
    <description>The following parameter will be assessed: rhinoconjunctivitis total symptom score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical tolerability and safety of the treatment</measure>
    <time_frame>8 months</time_frame>
    <description>The following parameters will be assessed: general physical status, vital signs, haematological parameters, general blodd biochemistry parameters, all (serious) adverse events, immunological analysis (total IgG, IgE) and inflammatory parameters (CRP, sedimentation rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of gpASIT+TM on the immunological status of the subjects</measure>
    <time_frame>screening visit (January-February 2011), before pollen season (April 2011), during pollen season (June 2011) and after pollen season (August 2011)</time_frame>
    <description>The following parameter will be assessed: allergen-specific immunoglobulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of gpASIT+TM on the clinical status of the subjects</measure>
    <time_frame>grass pollen season 2011 (April-July)</time_frame>
    <description>The average daily symptom and rescue medication scores will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of gpASIT+TM on the quality of life of the subjects</measure>
    <time_frame>grass pollen season 2011 (April-July)</time_frame>
    <description>The quality of life will be assessed by the use of validated questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Grass Pollen Allergy</condition>
  <condition>Hay Fever</condition>
  <arm_group>
    <arm_group_label>gpASIT400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gpASIT+TM 400 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gpASIT800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gpASIT+TM 800 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gpASIT+TM</intervention_name>
    <description>entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days</description>
    <arm_group_label>gpASIT400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gpASIT+TM</intervention_name>
    <description>entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days</description>
    <arm_group_label>gpASIT800</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo entero-coated capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years

          -  Subject has given written informed consent

          -  The subjects are in good physical and mental health according to his/her medical
             history, vital signs, and clinical status

          -  Male or non pregnant, non-lactating female

          -  Female unable to bear children must have documentation of such in the CRF (i.e. tubule
             ligation, hysterectomy, or post menopausal (defined as a minimum of one year since the
             last menstrual period))

          -  Allergy &gt; 2 years

        Exclusion Criteria:

          -  Subjects with current immunotherapy or subjects who underwent a previous immunotherapy
             within the last 2 years

          -  Subjects with perennial asthma

          -  Subjects with a VC &lt; 80% and FEV1 &lt; 70%

          -  Subjects requiring controller medication against asthma (bronchodilator nebulised
             drugs or local or systemic corticosteroids)

          -  Documented evidence of chronic sinusitis (as determined by investigator)

          -  Subjects with a history of hepatic or renal disease

          -  Subjects symptomatic to perennial inhalant allergens

          -  Subject with malignant disease, autoimmune disease

          -  Female subjects who are pregnant, lactating, or of child-bearing potential and not
             protected from pregnancy by a sufficiently reliable method (OCs, IUD, ...)

          -  Any chronic disease, which may impair the subject's ability to participate in the
             trial (i.e. severe congestive heart failure, active gastric ulcer, inflammatory bowel
             disease, uncontrolled diabetes mellitus, etc…)

          -  Subjects requiring beta-blockers medication

          -  Chronic use of concomitant medications that would affect assessment of the
             effectiveness of the trial medication (e.g. tricyclic antidepressants)

          -  Subject with febrile illness (&gt; 37.5°C, oral)

          -  A known positive serology for HIV-1/2, HBV or HCV

          -  The subject is immunocompromised by medication or illness, has received a vaccine,
             corticoids or immunosuppressive medications within 1 month before trial entry

          -  Receipt of blood or a blood derivative in the past 6 months preceding trial entry

          -  Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs
             within 4 weeks preceding the trial

          -  Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs
             within 1 week preceding the trial

          -  Use of long-acting antihistamines

          -  Any condition which could be incompatible with protocol understanding and compliance

          -  Subjects who have forfeited their freedom by administrative or legal award or who are
             under guardianship

          -  Unreliable subjects including non-compliant subjects, subjects with known alcoholism
             or drug abuse or with a history of a serious psychiatric disorder as well as subjects
             unwilling to give informed consent or to abide by the requirements of the protocol

          -  Participation in another clinical trial and/or treatment with an experimental drug
             within the last 2 years

          -  A history of hypersensitivity to the excipients

          -  Rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative agent…)

          -  Subjects without means of contacting the investigator rapidly in case of emergency, or
             not able to be contacted rapidly by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bachert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Ceuppens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Ebo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc Halloy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Warquignies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stijn Hallewyck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Hellings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renaud Louis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Liège</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Mbasoa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique du Parc Léopold Bruxelles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Pilette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Saint Luc Bruxelles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène Simonis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Citadelle Liège</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Vandenplas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Mont Godinne Yvoir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Verhoye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Lucas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Wackenier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Ambroise Paré Mons</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric De Blay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Christine Castelain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Vincent de Paul Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Lavaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoît Wallaert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Wessel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Lebeaupin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Hentges, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHL Luxembourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Durand Perdriel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Spirlet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Dinant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR Saint Joseph Warquignies</name>
      <address>
        <city>Boussu</city>
        <zip>7300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Parc Léopold</name>
      <address>
        <city>Brussels</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Nantes</city>
        <zip>44400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Allergy</keyword>
  <keyword>Grass pollen</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune system disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

